查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594389

NDDS 癌症治療市場：按類型、給藥方式、給藥途徑、應用和最終用戶分類 - 全球預測 2025-2030

NDDS in Cancer Therapy Market by Type (Dendrimers, Liposomes, Micelles), Mode (Controlled Drug Delivery Systems, Modulated Drug Delivery Systems, Targeted Drug Delivery Systems), Route of Administration, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，NDDS在癌症治療領域的市值為104.1億美元，預計到2024年將達到117.5億美元，複合年成長率為13.28%，到2030年將達到249.4億美元。

癌症治療中的新型藥物傳輸系統 (NDDS) 是一種變革性方法，旨在提高與癌症治療相關的療效、安全性和患者體驗。這些系統包括脂質體、奈米顆粒和單株抗體等先進方法，可將治療藥物標靶遞送並控制釋放到腫瘤部位，從而將常規化療常見的副作用降至最低。對 NDDS 的需求源於癌症盛行率的不斷上升以及對更有效、毒性更低的治療方法的迫切需求。 NDDS 的最終用途正在擴展到各種最終用途領域，包括醫院、診所和研究機構，其中精準醫療正變得越來越重要。

主要市場統計
基準年[2023] 104.1億美元
預測年份 [2024] 117.5億美元
預測年份 [2030] 249.4億美元
複合年成長率（%） 13.28%

推動 NDDS 在癌症治療中成長的關鍵因素包括給藥系統的技術進步、個人化醫療意識的提高以及製藥公司研發投資的增加。此外，對創新治療方法的監管支持和生技藥品的不斷採用也增加了市場潛力。然而，市場面臨著高開發成本、複雜的監管途徑以及與產品製造和檢驗相關的複雜性等挑戰。

可以透過專注於開發生物分解性和生物相容性的輸送系統來抓住機會，這些系統有望降低毒性風險。創新還可以致力於整合人工智慧和機器學習，以提高藥物輸送的精確度。與學術機構合作進行突破性研究可以帶來策略進步。此外，向醫療需求未滿足的新興市場擴張具有巨大的成長潛力。

然而，市場成長也可能受到技術複雜性和創新解決方案上市時間長的阻礙。為了克服這些挑戰，相關人員必須投資於持續的研究和開發，並與監管機構保持強力的合作，以簡化核准流程。市場的動態本質需要不斷適應，因此保持領先技術趨勢對於持續成長和競爭力至關重要。

市場動態：針對快速發展的癌症治療 NDDS 市場揭示的關鍵市場見解

供需的動態交互作用正在改變 NDDS 在癌症治療中的市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球癌症盛行率上升
    • 對 NDDS 提高藥物溶解度和降低毒性的需求日益成長
    • 加速投資開發新型癌症藥物輸送系統
  • 市場限制因素
    • 意識有限且成本高昂
  • 市場機會
    • 政府措施不斷湧現，加上優惠的報銷政策
    • 先進抗癌奈米藥物傳輸系統的持續研究活動
  • 市場挑戰
    • 缺乏技術精湛、經驗豐富的醫療專業人員

波特五力：開拓 NDDS 癌症治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解癌症治療市場 NDDS 的外部影響

外部宏觀環境因素在塑造 NDDS 在癌症治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解癌症治療 NDDS 市場的競爭狀況

對 NDDS 在癌症治療市場中的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

NDDS 市場 FPNV 定位矩陣癌症治療供應商績效評估

FPNV定位矩陣是評估癌症治療市場NDDS供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與推薦的癌症治療方法，為 NDDS 市場的成功指明道路

對於旨在加強在全球市場的影響力的公司來說，對癌症治療市場 NDDS 進行策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地的癌症發生率正在上升
      • NDDS 提高藥物溶解度和降低毒性的需求日益成長
      • 加速投資開發新型癌症藥物輸送系統
    • 抑制因素
      • 缺乏意識和參與造成巨大成本
    • 機會
      • 政府新措施與優惠報銷政策結合
      • 先進抗癌奈米藥物傳輸系統的研究活動
    • 任務
      • 缺乏技術精湛、經驗豐富的醫療專業人員
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第 6 章 NDDS 癌症治療市場：按類型

  • 樹狀聚合物
  • 脂質體
  • 膠束
  • 奈米粒子

第7章癌症治療市場中的NDDS（按模式）

  • 受管制藥物傳輸系統
  • 調控藥物傳輸系統
  • 標靶給藥系統

第 8 章 NDDS 癌症治療市場：依給藥途徑

  • 注射給藥系統
  • 口服給藥系統
  • 肺部給藥系統
  • 經皮給藥系統

第 9 章 NDDS 癌症治療市場：依應用分類

  • 腦腫瘤
  • 乳癌
  • 肺癌
  • 胰臟癌

第 10 章 NDDS 癌症治療市場：依最終使用者分類

  • 門診手術中心
  • 醫院
  • 專科診所

第11章 NDDS在美洲癌症治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區癌症治療NDDS市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲癌症治療的 NDDS 市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AstraZeneca
  • Boston Scientific Corporation
  • Cospheric LLC
  • Enable Injections
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Merit Medical Systems
  • MO-SCI Corporation
  • Novartis AG
  • Pacira BioSciences, Inc.
  • Pfizer Inc.
  • Samyang Holdings Corporation
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • West Pharmaceutical Services, Inc.
Product Code: MRR-521BAA36EBB7

The NDDS in Cancer Therapy Market was valued at USD 10.41 billion in 2023, expected to reach USD 11.75 billion in 2024, and is projected to grow at a CAGR of 13.28%, to USD 24.94 billion by 2030.

The Novel Drug Delivery Systems (NDDS) in cancer therapy represent a transformative approach aimed at improving the efficacy, safety, and patient experience associated with cancer treatment. These systems encompass advanced methods like liposomes, nanoparticles, and monoclonal antibodies, offering targeted delivery and controlled release of therapeutic agents at tumor sites, minimizing the adverse effects commonly associated with traditional chemotherapy. The necessity for NDDS arises from the increasing prevalence of cancer and the compelling demand for more effective and less toxic treatment modalities. Its applications extend across various end-use sectors, including hospitals, clinics, and research institutes, where precision medicine is increasingly prioritized.

KEY MARKET STATISTICS
Base Year [2023] USD 10.41 billion
Estimated Year [2024] USD 11.75 billion
Forecast Year [2030] USD 24.94 billion
CAGR (%) 13.28%

Key factors driving the growth of NDDS in cancer therapy include technological advancements in drug delivery systems, growing awareness about personalized medicine, and increased R&D investments by pharmaceutical companies. Additionally, regulatory support for innovative treatment options and the rising adoption of biologics are enhancing the market potential. However, the market faces challenges such as high development costs, complex regulatory pathways, and the intricacies involved in product manufacturing and validation.

Opportunities can be seized by focusing on the development of biodegradable and bio-compatible delivery systems, which are anticipated to mitigate risks of toxicity. Innovation could be directed towards the integration of artificial intelligence and machine learning to enhance precision in drug delivery. Collaborations with academic institutions for groundbreaking research can provide strategic advancements. Furthermore, expanding into emerging markets with unmet medical needs presents vast growth potential.

However, the market's growth could be hindered by technological complexities and the prolonged time-to-market for innovative solutions. To navigate these challenges, stakeholders should invest in continuous research and development, while also maintaining strong collaborations with regulatory bodies to streamline approval processes. The dynamic nature of the market requires constant adaptation, and staying ahead of technological trends will be crucial for sustained growth and competitiveness.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving NDDS in Cancer Therapy Market

The NDDS in Cancer Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cancer across the globe
    • Increasing need of NDDS to imrove drug solubility and reduce toxicity
    • Accelerating investments for development of novel drug delivery systems for cancer
  • Market Restraints
    • Limited awareness and involvement of huge cost
  • Market Opportunities
    • Emerging government initiatives coupled with favorable reimbursement policies
    • Ongoing research activities for advanced anti-cancer nano drug delivery system
  • Market Challenges
    • Dearth of skilled and experienced medical professionals

Porter's Five Forces: A Strategic Tool for Navigating the NDDS in Cancer Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the NDDS in Cancer Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the NDDS in Cancer Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the NDDS in Cancer Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the NDDS in Cancer Therapy Market

A detailed market share analysis in the NDDS in Cancer Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the NDDS in Cancer Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the NDDS in Cancer Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the NDDS in Cancer Therapy Market

A strategic analysis of the NDDS in Cancer Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the NDDS in Cancer Therapy Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca, Boston Scientific Corporation, Cospheric LLC, Enable Injections, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Merit Medical Systems, MO-SCI Corporation, Novartis AG, Pacira BioSciences, Inc., Pfizer Inc., Samyang Holdings Corporation, Sanofi S.A., Teva Pharmaceutical Industries Ltd., and West Pharmaceutical Services, Inc..

Market Segmentation & Coverage

This research report categorizes the NDDS in Cancer Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Dendrimers, Liposomes, Micelles, and Nanoparticles.
  • Based on Mode, market is studied across Controlled Drug Delivery Systems, Modulated Drug Delivery Systems, and Targeted Drug Delivery Systems.
  • Based on Route of Administration, market is studied across Injectable Drug Delivery Systems, Oral Drug Delivery Systems, Pulmonary Drug Delivery Systems, and Transdermal Drug Delivery Systems.
  • Based on Application, market is studied across Brain Cancer, Breast Cancer, Lung Cancer, and Pancreatic Cancer.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer across the globe
      • 5.1.1.2. Increasing need of NDDS to imrove drug solubility and reduce toxicity
      • 5.1.1.3. Accelerating investments for development of novel drug delivery systems for cancer
    • 5.1.2. Restraints
      • 5.1.2.1. Limited awareness and involvement of huge cost
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging government initiatives coupled with favorable reimbursement policies
      • 5.1.3.2. Ongoing research activities for advanced anti-cancer nano drug delivery system
    • 5.1.4. Challenges
      • 5.1.4.1. Dearth of skilled and experienced medical professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. NDDS in Cancer Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Dendrimers
  • 6.3. Liposomes
  • 6.4. Micelles
  • 6.5. Nanoparticles

7. NDDS in Cancer Therapy Market, by Mode

  • 7.1. Introduction
  • 7.2. Controlled Drug Delivery Systems
  • 7.3. Modulated Drug Delivery Systems
  • 7.4. Targeted Drug Delivery Systems

8. NDDS in Cancer Therapy Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injectable Drug Delivery Systems
  • 8.3. Oral Drug Delivery Systems
  • 8.4. Pulmonary Drug Delivery Systems
  • 8.5. Transdermal Drug Delivery Systems

9. NDDS in Cancer Therapy Market, by Application

  • 9.1. Introduction
  • 9.2. Brain Cancer
  • 9.3. Breast Cancer
  • 9.4. Lung Cancer
  • 9.5. Pancreatic Cancer

10. NDDS in Cancer Therapy Market, by End-User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Americas NDDS in Cancer Therapy Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific NDDS in Cancer Therapy Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa NDDS in Cancer Therapy Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AstraZeneca
  • 3. Boston Scientific Corporation
  • 4. Cospheric LLC
  • 5. Enable Injections
  • 6. GlaxoSmithKline PLC
  • 7. Johnson & Johnson Services, Inc.
  • 8. Merck & Co., Inc.
  • 9. Merit Medical Systems
  • 10. MO-SCI Corporation
  • 11. Novartis AG
  • 12. Pacira BioSciences, Inc.
  • 13. Pfizer Inc.
  • 14. Samyang Holdings Corporation
  • 15. Sanofi S.A.
  • 16. Teva Pharmaceutical Industries Ltd.
  • 17. West Pharmaceutical Services, Inc.

LIST OF FIGURES

  • FIGURE 1. NDDS IN CANCER THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. NDDS IN CANCER THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. NDDS IN CANCER THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. NDDS IN CANCER THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NDDS IN CANCER THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NDDS IN CANCER THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICELLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY CONTROLLED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MODULATED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TARGETED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY INJECTABLE DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ORAL DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PULMONARY DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TRANSDERMAL DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY BRAIN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 239. NDDS IN CANCER THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 240. NDDS IN CANCER THERAPY MARKET, FPNV POSITIONING MATRIX, 2023